acute cellular rejection

a·cute cel·lu·lar re·jec·tion

graft rejection that usually begins within 10 days after a graft has been transplanted into a genetically dissimilar host. Lesions at the site of the graft characteristically are infiltrated with large numbers of lymphocytes and macrophages that cause tissue damage. See: primary rejection.
Synonym(s): acute rejection
Mentioned in ?
References in periodicals archive ?
A higher age and weight at transplant, treatment for acute cellular rejection and polycystic kidney disease were found to be significantly associated with the risk of NODAT.
50%-75% of recipients experience acute cellular rejection, most commonly in the first 90 days, while chronic rejection (CR) occurs in 15% of patients (18).
Among these 3 (43 percent) patients were found to have chronic allograft nephropathy, 1 (14 percent) had Acute Cellular Rejection, 1 (14 percent) had combined acute cellular and chronic rejection and 2 (29 percent) patients were found to have no rejection in our study.
Both companies have well-established core products in transplantation: CareDx's AlloMap for acute cellular rejection in heart transplant patients, and Allenex's Olerup SSP for HLA matching of donors and recipients.
Even in situations whereby the pathologist is unable to come to a definitive conclusion, giving definite negative diagnoses such as the absence of histologic features for acute cellular rejection can be useful to the treating physician.
The company has commercialized AlloMap, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate/severe acute cellular rejection.
Intraoperative biopsy confirmed the kidney was still viable without evidence of infarct or acute cellular rejection.
The first study to consider this parameter as a risk factor for BCs - By the Hong Kong research group of Chok - Determined that acute cellular rejection was a significant risk factor for anastomotic stricture.
12 September 2014 - The US FDA said Thursday it had cleared Pleximmune, a first-in-class blood test by Pittsburgh-based biotech firm Plexision, for predicting acute cellular rejection of transplanted livers and intestines in pediatric patients.
This test predicts acute cellular rejection of transplanted livers and intestines in children.
The aim of the present study was to analyze the presence of HCMV and HHV-6 DNA in liver donor biopsies, seeking to better understand issues involving HLA-A, B, and DR donor, as well as associations with acute cellular rejection.

Full browser ?